Cardiovascular Therapeutics Market 2024-2028: Size and Advent of wearable defibrillators; growth driven by the Distribution Channel, Some of key Companies Positioned Strategically
The cardiovascular therapeutics market size by Distribution Channel (Hospital pharmacy, Retail Pharmacy, and Online pharmacy), Type (Antithrombotic drugs, Hypolipidemic drugs, and Others), and Geography (Asia, North America, Europe, and Rest of World (ROW)), is forecast to increase by USD 24.25 million. The market is expected to grow at a CAGR of 4.57% between 2024 and 2028.
- The cardiovascular therapeutics market is experiencing significant research and development investments in the production of wearable cardiovascular defibrillators. For example, the VEST trial, a randomized, multi-center study, assessed the effectiveness of Zoll's LifeVest wearable cardioverter defibrillator (WCD) in minimizing sudden death for heart attack survivors with a reduced ejection fraction of 35% or less. Despite ejection fraction enhancement post-heart attack, the initial three months pose an elevated risk for sudden death.
- In the APAC region, the cardiovascular therapeutics market is witnessing a surge in demand for automation solutions to streamline intricate production processes and enhance operational productivity. The expanding scale of operations leads to intricate supply chains, necessitating collaborations between established vendors and system integrators to broaden market reach and consolidate the fragmented cardiovascular therapeutics market. APAC's status as a global manufacturing hub is reinforced by substantial annual international investments and robust economic growth in developing countries.
Access the full report to know who are the other key countries segment-wise forecast and historic data
![](https://www.technavio.com/image/IRTNTR40101_nr_info_v5.jpg)
Some of the Key Companies:
- Abbott Laboratories
- Acutus Medical Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Viatris Inc.
- Aurobindo Pharma Ltd.
- Dr Reddys Laboratories Ltd.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/